Trastuzumab
Sold as Herceptin iv, Herclon, Herceptin sc, Hertraz, Hertraz iv, Ogivri, Ogivri iv, Kanjinti, Trastuzumab cipla, Herzuma, Hertuzu, Equttuz, Enhertu
No structure available
This product's active ingredient could not be matched to a single known compound.
Background
Registration
- Applicants
- 7
- Registrations
- 16
- Schedule source
- Consolidated Schedules 06 July 2026
Applicants and registrations
| Applicant | Brands | Dosages | Registrations | Schedule | Leaflets |
|---|---|---|---|---|---|
| Roche Products (Pty) Ltd1 of 3 cancelled | Herceptin iv, Herclon, Herceptin sc | 21 mg/ml, 600 mg | 340419, 460866, 481244 | S4 | PIPIL |
| Imperial Market Access Healthcare SA (Pty) LtdCertificate held by Imperial Market Access South Africa (Pty) Ltd. | Hertraz, Hertraz iv, Ogivri, Ogivri iv | 21 mg/ml, 150, 440 mg | 520213, 520214, 520215.213, 520216.214 | S4 | PIPIL |
| Amgen south africa (pty)ltdCancelled | Kanjinti | 150 mg, 420 mg | 520576, 520577 | S4 | None |
| Cipla Medpro (Pty) Ltd | Trastuzumab cipla | 440 mg | 530051 | S4 | None |
| Adcock ingram limited | Herzuma, Hertuzu | 150 mg, 440 mg | 530598, 530599, 530601.598, 530602.599 | S4 | None |
| Equity Pharmaceutical (Pty) Ltd | Equttuz | Not stated | 560441 | S4 | None |
| Astrazeneca Pharmaceuticals (Pty) LtdCertificate held by Astrazeneca Pharmaceuticals (Pty) Limited | Enhertu | 100 mg | 590013 | S4 | PIPIL |
Variants
| Product | Strength and form | Registration | Status | Schedule | Leaflets |
|---|---|---|---|---|---|
| Herceptin 21 mg/ml iv EACH VIAL CONTAINS TRASTUZUMAB 440,0 mg | 21 mg/ml | 34041934/26/0419 | Registered | S4 | None |
| Herclon EACH VIAL CONTAINS TRASTUZUMAB 440,0 mg | Not listed | 46086646/26/0866 | Cancelled | S4 | None |
| Herceptin sc 600 MG EACH 5,0 ml SOLUTION CONTAINS TRASTUZUMAB 600,0 mg | 600 mgConcentrate for solution for infusion | 48124448/26/1244Approved 8 August 2021 | Registered | S4 | PIPIL |
| Hertraz 150 EACH VIAL CONTAINS :TRASTUZUMAB 150,0 mg | 150 | 52021351/26/0213 | Registered | S4 | None |
| Hertraz 21 mg/ml iv EACH VIAL CONTAINS :TRASTUZUMAB 440,0 mg | 21 mg/ml | 52021452/26/0214 | Registered | S4 | None |
| Ogivri 150 EACH VIAL CONTAINS :TRASTUZUMAB 150,0 mg | 440 mgLyophilised powder for concentrate for solution for infusion | 520215.21352/26/0215.213Approved 9 September 2024 | Registered | S4 | PIPIL |
| Ogivri 21 mg/ml iv EACH VIAL CONTAINS :TRASTUZUMAB 440,0 mg | 21 mg/ml | 520216.21452/26/0216.214 | Registered | S4 | None |
| Kanjinti 150 MG EACH VIAL CONTAINS :TRASTUZUMAB 150,0 mg | 150 mg | 52057652/26/0576 | Cancelled | S4 | None |
| Kanjinti 420 MG EACH VIAL CONTAINS :TRASTUZUMAB 420,0 mg | 420 mg | 52057752/26/0577 | Cancelled | S4 | None |
| Trastuzumab cipla 440 MG EACH VIAL CONTAINS: TRASTUZUMAB 440,0 mg | 440 mg | 53005153/26/0051 | Registered | S4 | None |
| Herzuma 150 MG EACH VIAL CONTAINS TRASTUZUMAB 150,0 mg | 150 mg | 53059853/26/0598 | Registered | S4 | None |
| Herzuma 440 MG EACH VIAL CONTAINS TRASTUZUMAB 440,0 mg | 440 mg | 53059953/26/0599 | Registered | S4 | None |
| Hertuzu 150 MG EACH VIAL CONTAINS TRASTUZUMAB 150,0 mg | 150 mg | 530601.59853/26/0601.598 | Registered | S4 | None |
| Hertuzu 440 MG EACH VIAL CONTAINS TRASTUZUMAB 440,0 mg | 440 mg | 530602.59953/26/0602.599 | Registered | S4 | None |
| Equttuz EACH VIAL CONTAINS TRASTUZUMAB 440,0 mg | Not listed | 56044156/26/0441 | Registered | S4 | None |
| Enhertu EACH VIAL CONTAINS: TRASTUZUMAB DERUXTECAN 100,0 mg | 100 mgPowder for concentrate for solution for infusion. | 59001359/26/0013Approved 11 August 2026 | Registered | S4 | PIPIL |
Regulatory status
Where S4 sits on the scale
Prescription-only medicine.
Schedule 4 covers most ordinary prescription medicines. You need a prescription from an authorised prescriber, such as a doctor or dentist, and a pharmacist dispenses it. Its price, name, pack size and strength can still be told to the public, as long as nothing links it to what it treats.
Schedule S4, matched to the Consolidated Schedules by ingredient, confidence high.
Who may supply: A pharmacist dispensing against a written or verbal prescription from an authorised prescriber; a veterinarian, who may also prescribe, compound or dispense it directly; a medical practitioner or dentist, who may prescribe it and may compound or dispense it directly only if licensed under section 22C(1)(a); manufacturers and wholesalers may supply people who may lawfully possess it; and, for animal treatment, a person practising a para-veterinary profession, on a veterinarian's written or verbal instruction.
Consolidated Schedules listings for Trastuzumab
S4: Trastuzumab
Consolidated Schedules 06 July 2026, line 8261
Pharmacological class: Cytostatic agents (class 26)
This is an informational summary of the Medicines and Related Substances Act 101 of 1965 and its 2017 General Regulations. It is not medical advice and not legal advice. Always check the medicine's label, which carries the schedule number inside a square border, or ask a pharmacist if you are unsure.
SAHPRA documents
These documents are provided by SAHPRA for informational purposes. Always consult with a healthcare professional for medical advice.